ERBB2 and gastric cancer: Importantly, IQGAP1 overexpression in HER2-positive breast and gastric cancer cells induces resistance to trastuzumab, a therapeutic monoclonal antibody targeted at HER2, likely by stabilizing active HER2 (Arienti et al., 2016; White et al., 2011).